Global Major Depressive Disorder (MDD) Treatment Market
Major depressive disorder (MDD), also known as clinical depression, is a mental health disorder which affects mood, behavior, as well as appetite and sleep. The exact cause of MDD is not known; however, several factors that can potentially increase its risk include a combination of genes and stress that affect the brain’s chemistry and reduce its ability to maintain mood stability. Hormonal imbalance, alcohol or drug abuse, certain medical conditions such as cancer or hypothyroidism, and some adverse side effects of medications such as steroids, can also lead to MDD. Changing lifestyles, work pressure, alcohol abuse, and other similar aspects have resulted in an increased prevalence of MDD, which is expected to drive the global market growth during the forecast period. According to an article published in the National Center for Biotechnology Information in 2015, MDD is the most common psychiatric disorder found in India and the lifetime prevalence of MDD is around 10% to 25% in women, and 5% to 12% in men.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1217
Increasing FDA approvals for new drugs is expected to drive the global MDD treatment market growth
Major depressive disorder treatment market is witnessing a dynamic change, where patents for drugs such as Cymbalta and Abilify has expired recently, and revenue generated from these drugs plummeted with the introduction of generics. Therefore, approval of new drugs such as Levomilnacipran, Brintellix, and Rexulti (brexpiprazole) is a primary driver for this market growth. FDA approved Levomilnacipran — a new serotonin-norepinephrine reuptake inhibitor (SNRI) — for major depressive disorder (MDD) in adults in 2013. In the same year, Takeda Pharmaceutical Company Limited and H. Lundbeck A/S announced the FDA approval for Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD). Rexulti (brexpiprazole) tablets received approval from FDA as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD) in July, 2015. These approvals are expected to provide more option to patients suffering from MDD, and this is expected to support the major depressive disorder treatment market growth.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3tlzuDp
Global Major Depressive Disorder (MDD) Treatment Market Taxonomy
On the basis of product type, the global major depressive disorder (MDD) treatment market is segmented into:
- Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIS)
- Lexapro (Escitalopram)
- Viibryd (Vilazodone)
- Dopamine Norepinephrine Reuptake Inhibitor
- Serotonin Norepinephrine Reuptake Inhibitor
- Cymbalta (Duloxetine)
- Effexor (Venlafaxine)
- Fetzima (Levomilnacipran)
- Savella (Milnacipran)
- Pristiq (Desvenlafaxine)
- Serotonin Modulators
- Norepinephrine-Serotonin Modulator
- Tricyclics and Tetracyclics
- Selective Serotonin Reuptake Inhibitors (SSRIS)
- Atypical Antidepressants
- Antipsychotics
- Abilify (Aripiprazole)
- Seroquel XR (Quetiapine XR)
- Rexulti (Brexpiprazole)
- Neuromodulators
- Stem Cell Therapy
- Antidepressants
North America to dominate the global market in the forthcoming years, owing to surging prevalence of MDD
North America is expected to hold a dominant stance in the global major depressive disorder treatment market, due to increasing prevalence of MDD in the U.S. As per a 2015 survey by the National Institute of Mental Health, an estimated 16.1 million adults in the U.S., aged 18 years and above, had at least one major depressive episode in the past year. Europe is expected to be the second largest market for MDD treatment, due to rapid regulatory approval of new therapies. For instance, in 2015, Soterix Medical received a CE Marking for its new tDCS depressive disorder therapy used for the treatment of MDD.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/major-depressive-disorder-treatment-market-1217
Key Market Players
The significant players operating in the global major depressive disorder treatment market are Eli Lilly and Company, Allergan, Alkermes, Lundbeck, Johnson & Johnson, Pfizer, Inc., AstraZeneca Plc, Merck & Co., GlaxoSmithKline Plc. Sanofi S.A., and Takeda Pharmaceutical Company Limited.
Table of Content
Global Major Depressive Disorder (MDD) Treatment Market Research Report
Section 1: Global Major Depressive Disorder (MDD) Treatment Industry Overview
Section 2: Global Economic Impact on Major Depressive Disorder (MDD) Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Major Depressive Disorder (MDD) Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Major Depressive Disorder (MDD) Treatment Market Forecast
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837